Clinical trials: Hospitalized COVID-19
Covid19, Diaphragm Injury
Respiratory Muscle Assesment in COVID-patients Without Hospitalization
Fatigue and exercise intolerance after survived COVID-19-infection might be related to weakness of the respiratory muscles. The aim of the project is to measure respiratory muscle function and strength in our respiratory…
- Trial name
- RMA-COVID-19 (NCT06105450)
- Testing
- Comprehensive assessment of respiratory muscle function.
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- RWTH Aachen University
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19 Infection
Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19
EC CORONACOLCHI is a multicenter, double-blind and randomized clinical trial with two branches. Patients who meet all the inclusion criteria and none of the exclusion criteria will be randomized 1: 1 to be included in one of the…
- Trial name
- NCT04997551
- Testing
- Colchcine
- Where
- Spain
- Volunteers
- 752 people
- Sponsor
- Biogipuzkoa Health Research Institute
Infections, Coronavirus
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19
Convalescent plasma is a way to provide passive immunity to a person exposed to an infectious agent. It has been used as a therapeutic tool for emerging viral infections without specific treatment and with high morbidity and…
- Trial name
- NCT04385186
- Testing
- Inactivated convalescent plasma, Support treatment
- Where
- 10 sites in Colombia
- Volunteers
- 60 people
- Sponsor
- National Blood Center Foundation, Hemolife
COVID-19 Pneumonia
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in adults hospitalized with COVID-19…
- Trial name
- NCT04460105
- Testing
- Lanadelumab
- Sponsor
- Shire
COVID-19
ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04583956
- Testing
- Remdesivir, Risankizumab
- Where
- 32 sites in United States
- Volunteers
- 214 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Infection
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory…
- Trial name
- NCT04346615
- Testing
- Zavegepant (BHV-3500)
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
COVID
Convalescent Plasma vs. Standard Plasma for COVID-19
The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat…
- Trial name
- NCT04344535
- Testing
- Convalescent Plasma, Standard Donor Plasma
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Stony Brook University
SARS-CoV-2 Infection, COVID-19
The Vietnam Chloroquine Treatment on COVID-19
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or therapeutic agent to treat COVID-19.
- Trial name
- VICO (NCT04328493)
- Testing
- Chloroquine phosphate
- Where
- 5 sites in Vietnam
- Volunteers
- 10 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
COVID-19, Post Acute Sequelae of COVID-19
COVID-19 Outcome Prediction Algorithm
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system.
- Conditions
- COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple
- Trial name
- COPA (NCT05471011)
- Testing
- Blood and nasal swab sampling
- Where
- 7 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of California, Los Angeles
Covid19, Diaphragm Injury
Respiratory Muscles After Hospitalisation for COVID-19
Fatigue and exercise intolerance after survived COVID-19-infection might be related to weakness of the respiratory muscles especially following invasive mechanical ventilation in the Intensive Care Unit.
- Trial name
- REMAP-COVID-19 (NCT04854863)
- Testing
- Comprehensive assessment of respiratory muscle function.
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- RWTH Aachen University
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high…
- Trial name
- NCT04432324
- Testing
- Intravenous Immune Globulin, Standard Medical Treatment
- Where
- 10 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Instituto Grifols, S.A.
Covid19, Hospitalization
Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients
The primary objective of this study is to evaluate the current management approach with "intermediate" or "therapeutic" doses of tinzaparin for thromboprophylaxis in hospitalized patients, non on ICU organ support, with confirmed…
- Trial name
- INTERACT (NCT05036824)
- Testing
- tinzaparin
- Where
- 7 sites in Greece
- Volunteers
- 300 people
- Sponsor
- University Hospital of Patras
COVID19
Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection
The aim of this study is to analyze the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection.
- Trial name
- NCT04432922
- Testing
- Hospitalized Patients for COVID-19 Infection
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Patients Hospitalized in the Hospices Civils of Lyon, COVID-19 Disease
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically.
- Conditions
- Patients Hospitalized in the Hospices Civils of Lyon, COVID-19 Disease, Moderate to Severe Dyspnea, Without Resuscitation Objective Management
- Trial name
- CODYS (NCT04522037)
- Testing
- No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Covid19
Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection
The objective of the study is to evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized patients with COVID-19.
- Trial name
- NCT04636086
- Testing
- Cholecalciferol
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University of Liege
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04312009
- Testing
- Losartan
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- University of Minnesota
Corona Virus Infection
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe coronavirus disease 2019…
- Trial name
- NCT04469621
- Testing
- SAR443122
- Where
- 10 sites in Argentina, Brazil and 3 more
- Volunteers
- 68 people
- Sponsor
- Sanofi
COVID-19
Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
To apply and compare two different methodological approaches (one applying diagnostics steps and contingencies and the other not) to the illustrative example described below: Illustrative Example - Objective I aims to…
- Trial name
- NCT05638932
- Testing
- Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
- Where
- United States
- Volunteers
- 1,442 people
- Sponsor
- Aetion, Inc.